Daniel N. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel N. Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Powell Dolan
Brigham and Women's Hospital Boston Massachusetts USA
4 shared publications Raphael Bueno
Division of Thoracic Surgery Brigham and Women's Hospital Boston Massachusetts USA
4 shared publicationsAbby White
Division of Thoracic Surgery Brigham and Women's Hospital Boston Massachusetts USA
3 shared publicationsMichael T. Jaklitsch
Division of Thoracic Surgery Brigham and Women's Hospital Boston Massachusetts USA
3 shared publicationsScott J. Swanson
Division of Thoracic Surgery Brigham and Women's Hospital Boston Massachusetts USA
3 shared publicationsSuden Kucukak
Division of Thoracic Surgery Brigham and Women's Hospital Boston Massachusetts USA
3 shared publications
Latest Publications
- 1 December 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (4) , 734-740
Hyperthermic intraoperative chemotherapy (HIOC) for Stage IVa thymic malignancy may improve 5‐year disease‐free survival
Background and Objectives: Stage IVa thymic malignancy has limited treatments. This study evaluated whether hyperthermic intraoperative chemotherapy (HIOC) after radical resection of Stage IVa thymic malignancy improves survival.Methods: All patients who underwent resection, with or without HIOC, for Stage IVa thymic malignancy at a single center from 1990 to 2021 were reviewed.Results: Thirty‐four patients were identified; 22 surgery‐only versus 12 surgery and HIOC (60 min cisplatin regimen 175 mg/m2). Demographics and comorbidities were similar between groups. Three patients in each group were carcinomas; remainder were thymomas. Thirty‐two patients underwent attempted macroscopic complete resection; 22 operations succeeded, 68.8%. Significant complications were similar between groups, 18.2% surgery‐only versus 25.0% HIOC, p = 0.68. Median time to recurrence trended longer for HIOC patients (42.9 vs. 32.9 months in surgery‐only, p = 0.77). Overall survival, 5‐year, was similar (75.8% HIOC vs. 76.2% surgery‐only, p = 0.91). On stratified analysis, thymoma patients with macroscopic complete resection and HIOC experienced similar 5‐year Overall (80.0% vs. 100.0% surgery‐only, p = 0.157) but longer trending 5‐year disease‐free (85.7% vs. 40.0%, p = 0.18) and 5‐year locoregional recurrence‐free survival (85.7% vs. 68.6%, p = 0.75).Conclusions: This retrospective cohort study treating Stage IVa thymic malignancy with radical pleurectomy, with or without HIOC, found addition of HIOC‐signaled delayed recurrence and improved disease‐free survival.
- 1 December 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 127 (4) , 734-740
Hyperthermic intraoperative chemotherapy (HIOC) for Stage IVa thymic malignancy may improve 5‐year disease‐free survival
Background and Objectives: Stage IVa thymic malignancy has limited treatments. This study evaluated whether hyperthermic intraoperative chemotherapy (HIOC) after radical resection of Stage IVa thymic malignancy improves survival.Methods: All patients who underwent resection, with or without HIOC, for Stage IVa thymic malignancy at a single center from 1990 to 2021 were reviewed.Results: Thirty‐four patients were identified; 22 surgery‐only versus 12 surgery and HIOC (60 min cisplatin regimen 175 mg/m2). Demographics and comorbidities were similar between groups. Three patients in each group were carcinomas; remainder were thymomas. Thirty‐two patients underwent attempted macroscopic complete resection; 22 operations succeeded, 68.8%. Significant complications were similar between groups, 18.2% surgery‐only versus 25.0% HIOC, p = 0.68. Median time to recurrence trended longer for HIOC patients (42.9 vs. 32.9 months in surgery‐only, p = 0.77). Overall survival, 5‐year, was similar (75.8% HIOC vs. 76.2% surgery‐only, p = 0.91). On stratified analysis, thymoma patients with macroscopic complete resection and HIOC experienced similar 5‐year Overall (80.0% vs. 100.0% surgery‐only, p = 0.157) but longer trending 5‐year disease‐free (85.7% vs. 40.0%, p = 0.18) and 5‐year locoregional recurrence‐free survival (85.7% vs. 68.6%, p = 0.75).Conclusions: This retrospective cohort study treating Stage IVa thymic malignancy with radical pleurectomy, with or without HIOC, found addition of HIOC‐signaled delayed recurrence and improved disease‐free survival.
- 23 May 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (4) , 814-822
Salvage surgery for local recurrence after sublobar surgery in Stages I and II non‐small cell lung cancer
Background and Objectives: To examine if patients undergoing salvage surgery for local recurrence following sublobar resection (SLR) have similar perioperative complications and overall survival (OS) compared to lobectomy patients for early stage non‐small cell lung cancer (NSCLC).Methods: Patients undergoing lobectomy and SLR (segmentectomy or wedge resection) for Stages I and II NSCLC from 2010 to 2016 were reviewed. Lobectomy patients and those who underwent salvage surgery for local recurrence after SLR were compared. Salvage surgeries were curative‐intent resections for recurrence.Results: Cases included 634 lobectomies and 986 SLR. Fifty‐nine SLR patients (6.0%) recurred at a local site compared to 11 lobectomy patients (1.7%; p < 0.001). Twenty‐three locally recurrent SLR patients (39.0%) went on to salvage surgery. Peri‐operative complications after salvage surgeries were similar to lobectomies (34.8% 8/23 vs. 34.7% 220/634, p = 1.00). OS at 5 years for salvage surgery patients was similar to lobectomy patients (79.6% 13/23 vs. 70.6% 227/634, p = 0.23). OS for patients who underwent salvage surgery was significantly better than those who did not have salvage surgery for recurrence (79.6% vs. 53.0%, p = 0.02).Conclusions: Patients who undergo salvage surgery for local recurrence after SLR had similar perioperative complications and OS compared to lobectomy patients but less than half underwent salvage surgery.
- 23 May 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 126 (4) , 814-822
Salvage surgery for local recurrence after sublobar surgery in Stages I and II non‐small cell lung cancer
Background and Objectives: To examine if patients undergoing salvage surgery for local recurrence following sublobar resection (SLR) have similar perioperative complications and overall survival (OS) compared to lobectomy patients for early stage non‐small cell lung cancer (NSCLC).Methods: Patients undergoing lobectomy and SLR (segmentectomy or wedge resection) for Stages I and II NSCLC from 2010 to 2016 were reviewed. Lobectomy patients and those who underwent salvage surgery for local recurrence after SLR were compared. Salvage surgeries were curative‐intent resections for recurrence.Results: Cases included 634 lobectomies and 986 SLR. Fifty‐nine SLR patients (6.0%) recurred at a local site compared to 11 lobectomy patients (1.7%; p < 0.001). Twenty‐three locally recurrent SLR patients (39.0%) went on to salvage surgery. Peri‐operative complications after salvage surgeries were similar to lobectomies (34.8% 8/23 vs. 34.7% 220/634, p = 1.00). OS at 5 years for salvage surgery patients was similar to lobectomy patients (79.6% 13/23 vs. 70.6% 227/634, p = 0.23). OS for patients who underwent salvage surgery was significantly better than those who did not have salvage surgery for recurrence (79.6% vs. 53.0%, p = 0.02).Conclusions: Patients who undergo salvage surgery for local recurrence after SLR had similar perioperative complications and OS compared to lobectomy patients but less than half underwent salvage surgery.
- Open Access
- 2 April 2022
- Published by Elsevier in JTCVS Techniques
- Vol. 14, 130-135
How I do it: Multiport video-assisted thoracoscopic surgery of the right middle lobe for non–small cell lung cancer: Right middle lobectomy in 12 steps
- 2 April 2022
- Published by Elsevier in JTCVS Techniques
- Vol. 14, 130-135
Open AccessHow I do it: Multiport video-assisted thoracoscopic surgery of the right middle lobe for non–small cell lung cancer: Right middle lobectomy in 12 steps
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (2) , 712-723
Survival and Recurrence Following Wedge Resection Versus Lobectomy for Early-Stage Non-Small Cell Lung Cancer
- 1 January 2022
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 34 (2) , 712-723
Survival and Recurrence Following Wedge Resection Versus Lobectomy for Early-Stage Non-Small Cell Lung Cancer
- 1 December 2020
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (2) , 570-578
Outcomes of superior segmentectomy versus lower lobectomy for superior segment Stage I non‐small‐cell lung cancer are equivalent: An analysis of 196 patients at a single, high volume institution
Objectives: To determine if superior segmentectomy has equivalent overall (OS), disease‐free (DFS), and locoregional‐recurrence‐free survival (LRFS) to lower lobectomy for early‐stage non‐small‐cell lung cancer (NSCLC) in the superior segment.Methods: We retrospectively reviewed all Stage 1 lower lobectomies for superior segment lesions and superior segmentectomies at our hospital from 2000 to 2018. Comparison statistics and Cox hazard modeling were performed to determine differences between groups and attempt to identify risk factors for OS, DFS, and LRFS.Results: Superior segmentectomy patients, compared with lower lobectomy patients, had more current smokers, worse forced expiratory volume in 1 s percentage, radiologic emphysema scores, clinically and pathologically smaller tumors, and more occurrences of 0 lymph nodes examined. Outcomes for superior segmentectomy compared with lower lobectomy were equivalent for 5‐year OS (67.0% vs. 75.1%, p = 0.70), DFS (56.9% vs. 60.4%, p = 0.59), and LRFS (87.9% vs. 91.3%, p = 0.46). Multivariable Cox modeling lacked utility due to no outcome differences.Conclusions: In well‐selected patients, superior segmentectomies can have equivalent OS, DFS, and LRFS compared with lower lobectomies of superior segment tumors for early stage lung cancer. Further data are needed to provide better risk estimates.
- 1 December 2020
- Published by Wiley in Journal of Surgical Oncology
- Vol. 123 (2) , 570-578
Outcomes of superior segmentectomy versus lower lobectomy for superior segment Stage I non‐small‐cell lung cancer are equivalent: An analysis of 196 patients at a single, high volume institution
Objectives: To determine if superior segmentectomy has equivalent overall (OS), disease‐free (DFS), and locoregional‐recurrence‐free survival (LRFS) to lower lobectomy for early‐stage non‐small‐cell lung cancer (NSCLC) in the superior segment.Methods: We retrospectively reviewed all Stage 1 lower lobectomies for superior segment lesions and superior segmentectomies at our hospital from 2000 to 2018. Comparison statistics and Cox hazard modeling were performed to determine differences between groups and attempt to identify risk factors for OS, DFS, and LRFS.Results: Superior segmentectomy patients, compared with lower lobectomy patients, had more current smokers, worse forced expiratory volume in 1 s percentage, radiologic emphysema scores, clinically and pathologically smaller tumors, and more occurrences of 0 lymph nodes examined. Outcomes for superior segmentectomy compared with lower lobectomy were equivalent for 5‐year OS (67.0% vs. 75.1%, p = 0.70), DFS (56.9% vs. 60.4%, p = 0.59), and LRFS (87.9% vs. 91.3%, p = 0.46). Multivariable Cox modeling lacked utility due to no outcome differences.Conclusions: In well‐selected patients, superior segmentectomies can have equivalent OS, DFS, and LRFS compared with lower lobectomies of superior segment tumors for early stage lung cancer. Further data are needed to provide better risk estimates.